High Numbers of CD163+ Tumor-Associated Macrophages Predict Poor Prognosis in HER2+ Breast Cancer
Cancers · 01.02.2024 · 16 (3) · 634
DOI: 10.3390/cancers16030634 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 01.02.2024. Verfasst von Minna M Jääskeläinen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, Kuopio University Hospital, Wellbeing Services County of North Savo, 70029 Kuopio, Finland. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Finnish Society for Oncology, Cancer Society of North Savo.
Abstract (Originalsprache)
Tumor-associated macrophages (TAMs) are associated with a poor outcome in breast cancer (BC), but their prognostic value in different BC subtypes has remained somewhat unclear. Here, we investigated the prognostic value of M2-like TAMs (CD163+) and all TAMs (CD68+) in a patient cohort of 278 non-metastatic BC patients, half of whom were HER2+ (n = 139). The survival endpoints investigated were overall survival (OS), breast cancer-specific survival (BCSS) and disease-free survival (DFS). In the whole patient cohort (n = 278), a high CD163+ TAM count and a high CD68+ TAM count were associated with a worse outcome (p ≤ 0.023). In HER2+ BC, a high CD163+ TAM count was an independent factor for a poor prognosis across all the investigated survival endpoints (p < 0.001). The prognostic effect was evident in both the HER2+/hormone receptor-positive (p < 0.001) and HER2+/hormone receptor-negative (p ≤ 0.012) subgroups and regardless of the provision of adjuvant trastuzumab (p ≤ 0.002). In HER2-negative BC, the CD163+ TAM count was not significantly associated with survival. These results suggest that a high CD163+ TAM count predicts an inferior outcome, especially in HER2+ BC patients, and as adjuvant trastuzumab did not overcome the poor prognostic effect, combination treatments including therapies targeting the macrophage function could represent an effective therapeutic approach in HER2+ BC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cancer Center, Kuopio University Hospital, Wellbeing Services County of North Savo, 70029 Kuopio, Finland.
- Institute of Clinical Medicine, University of Eastern Finland, 70211 Kuopio, Finland.
- Kuopio Center for Gene and Cell Therapy, 70210 Kuopio, Finland.
- Institute of Clinical Medicine, Clinical Pathology and Forensic Medicine, University of Eastern Finland, 70211 Kuopio, Finland.
- Imaging Center, Clinical Pathology, Kuopio University Hospital, Wellbeing Services County of North Savo, 70029 Kuopio, Finland.
- Biocenter Kuopio and Cancer Center of Eastern Finland, University of Eastern Finland, 70211 Kuopio, Finland.
ORCID-Profile: Ritva Tumelius, Kirsi Rilla, Aino Rönkä
Förderung
- Finnish Society for Oncology
- Cancer Society of North Savo
Zitieren
APA
Jääskeläinen, M. M., Tumelius, R., Hämäläinen, K., Rilla, K., Oikari, S., Rönkä, A., Selander, T., Mannermaa, A., Tiainen, S., & Auvinen, P. (2024). High Numbers of CD163+ Tumor-Associated Macrophages Predict Poor Prognosis in HER2+ Breast Cancer. Cancers, 16(3), 634. https://doi.org/10.3390/cancers16030634
Vancouver
Jääskeläinen MM, Tumelius R, Hämäläinen K, Rilla K, Oikari S, Rönkä A, et al. High Numbers of CD163+ Tumor-Associated Macrophages Predict Poor Prognosis in HER2+ Breast Cancer. Cancers. 2024;16(3):634. doi:10.3390/cancers16030634
BibTeX
@article{Jskelinen2024,
author = {Jääskeläinen, Minna M and Tumelius, Ritva and Hämäläinen, Kirsi and Rilla, Kirsi and Oikari, Sanna and Rönkä, Aino and Selander, Tuomas and Mannermaa, Arto and Tiainen, Satu and Auvinen, Päivi},
title = {High Numbers of CD163+ Tumor-Associated Macrophages Predict Poor Prognosis in HER2+ Breast Cancer},
journal = {Cancers},
year = {2024},
volume = {16},
number = {3},
pages = {634},
doi = {10.3390/cancers16030634}
}
EUVIMED